Sun Pharmaceutical wins tariff relief in new US drug pricing agreement

Sun Pharmaceutical said its agreement with the U.S. government carries more than two years of relief from Section 232 pharmaceutical tariffs, giving the company cost certainty for its innovative portfolio ^[2]. The deal was among a batch President Donald Trump announced in the Oval Office on Aug 31, 2026, alongside executives from Astellas, BeOne Medicines, CSL, BridgeBio and UCB SA ^[1].

Tariff relief has become the main thing manufacturers receive in return for pricing commitments. Under the agreements announced that day, the companies offered drugs to state Medicaid programs at most-favored-nation prices, meaning the lowest price a manufacturer charges elsewhere. Trump called it "a tremendous discount, which should bring down the cost of your medical care by tremendous amounts" ^[1].

What those discounts are worth is not public. The White House released no details, and the companies described parts of the terms as private ^[1]. Neither the number of medicines covered nor the size of the price cuts has been disclosed, so the effect on government spending and on patients' costs is unknown ^[1]. The administration and several companies said there would be additional savings on innovative drugs later, along with commitments to make more products in the United States ^[1].

Israel's Teva attended the event but said in a press release it is still negotiating ^[1].

The Aug 31 round builds on agreements with 17 of the largest drugmakers, among them Pfizer, Eli Lilly and Novo Nordisk, signed starting last year ^[1]. Those companies agreed to lower some prices for federal health programs and to sell certain medicines directly to patients through a Trump-branded website, in exchange for relief from tariffs ^[1]. How long that relief lasts in the earlier deals has not been reported ^[1].

Weight-loss medicines have produced the largest savings so far. Novo Nordisk and Eli Lilly accepted price cuts in return for wider Medicare availability of their drugs ^[1]. Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services, said 600,000 seniors had sought prescriptions through a temporary pilot that started July 1 ^[1]. The program's end date and the products it covers have not been announced ^[1].

Not everyone treats the deals as progress. Peter Maybarduk, access to medicines director at the consumer group Public Citizen, called them "a distraction from the administration's failed plan to lower U.S. drug prices to the levels paid in other wealthy countries" ^[1]. Medicaid already receives steep statutory discounts from manufacturers, and most of its enrollees pay little at the pharmacy counter ^[1].

Smaller and mid-sized companies have been slow to join. A Reuters report in June found that only Astellas had confirmed applying for the Medicaid pricing program, and executives at firms such as Ionis Pharmaceuticals said they saw little financial benefit ^[1]. The White House has said its broader pricing push could save $64.3 billion in federal and state spending over ten years, a figure Reuters described as speculative ^[1]. Americans pay close to three times as much for prescription drugs as people in other developed countries ^[1].

Why it matters for patients

Nothing in the Aug 31 announcements establishes a change in what any individual pays. The drugs covered and the discounts are undisclosed ^[1], and Sun Pharmaceutical has not said which products its agreement applies to ^[1][2]. For Medicaid enrollees the practical effect may be small, because that program already gets steep discounts and most members pay little out of pocket ^[1]. Medicare beneficiaries using weight-loss medicines have seen the most concrete change, through the earlier Lilly and Novo Nordisk deals that tied lower prices to broader Medicare access ^[1]. Whether tariff relief alters the list price or the copay of any GLP-1 medicine has not been reported ^[1].

What happens next

Teva said it continues talking with the administration about a possible agreement ^[1]. Companies and the administration said more savings on innovative medicines and more U.S. manufacturing would follow, without publishing terms ^[1]. The Medicare pilot that opened July 1 is described as temporary, with no end date announced ^[1].